This proposed acquisition is for an Illumina NextSeq 500 next-generation sequencer and associated ancillary hardware and software. Currently the Influenza Sequencing activity utilizes Illumina instruments and chemistry in order to the generate sequence for the surveillance of influenza. The NextSeq instrument is a higher capacity out put Illumina instrument that is able to utilize the same library chemistry that is currently utilized by the ISA team. The team has a fully developed informatics and analysis pipeline that will is calibrated and designed for the Data from the Illumina chemistry. Further, NextSeq instrument is compatible with the SOP's/ and reagents currently utilized in the Influenza division to generate whole genomic sequence. NextSeq is the only instrument that will accommodate the teams process and fill need without requiring changing SOP's, analysis, and chemistry.

Bid Protests Not Available